Trial Profile
A study of recombinant human bone morphogenetic protein–2 (rhBMP-2) in patients undergoing anterior lumbar interbody fusion (ALIF)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Dec 2015
Price :
$35
*
At a glance
- Drugs Dibotermin alfa (Primary)
- Indications Spinal disorders
- Focus Adverse reactions
- 16 Dec 2015 New trial record